Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’
2018 ◽
Vol 118
(9)
◽
pp. 1276-1277
◽
2017 ◽
Vol 117
(10)
◽
pp. 1450-1458
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 11038-11038
◽
2011 ◽
Vol 02
(05)
◽
pp. 675-682
◽
2010 ◽
Vol 16
(10)
◽
pp. 1177
◽
2013 ◽
Vol 38
(2)
◽
pp. 279-285
2014 ◽
Vol 29
(4)
◽
pp. 197-203
◽
2013 ◽
Vol 72
(2)
◽
pp. 397-403
◽